This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Aspirin in Alzheimer's disease

Authoring team

  • aspirin in Alzheimer's disease (AD)
    • study evidence revealed that treatment with low-dose aspirin had no worthwhile benefit in patients with AD and increased the risk of serious bleeds (1)
    • the AD2000 study shows that, for patients with AD and no clinically evident cardiovascular disease, transient ischaemic attack, or stroke, 2 years of treatment with low-dose aspirin
    • 8% patients on aspirin and 1% patients in the control group had bleeds that led to admission to hospital (relative risk=4·4, 95% CI 1·5–12·8; p=0·007); 2% patients in the aspirin group had fatal cerebral bleeds.

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.